ScreenPoint Medical Leads Breast Cancer Risk Evaluation with Biomediq Acquisition

In a strategic move to enhance its breast cancer risk assessment capabilities, ScreenPoint Medical has announced the acquisition of Biomediq A/S, a Danish enterprise specializing in the development and implementation of quantitative imaging biomarkers. This acquisition is set to integrate Biomediq's advanced mammographic texture risk biomarker technology with ScreenPoint's AI system, Transpara, which is designed to improve early detection and risk prediction for breast cancer. The integration follows years of collaboration between the two firms and aims to leverage Biomediq's expertise to extend Transpara's risk evaluation with tools for lesion detection, mammographic density assessment, and quantitative texture analysis. The transaction is expected to significantly enhance the prediction and early detection of interval cancers in women at high risk, effectively complementing traditional screening methods. The initiative underscores ScreenPoint’s commitment to advancing AI-driven risk stratification and personalized care in mammography, aligning with broader efforts to optimize screening resources and patient outcomes worldwide.